Cargando…
A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance
The practice of prophylactic administration of a macrolide antimicrobial with rifampin (MaR) to apparently healthy foals with pulmonary lesions identified by thoracic ultrasonography (i.e., subclinically pneumonic foals) is common in the United States. The practice has been associated epidemiologica...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976650/ https://www.ncbi.nlm.nih.gov/pubmed/31969575 http://dx.doi.org/10.1038/s41598-020-57479-9 |
_version_ | 1783490349221543936 |
---|---|
author | Álvarez–Narváez, S. Berghaus, L. J. Morris, E. R. A. Willingham-Lane, J. M. Slovis, N. M. Giguere, S. Cohen, N. D. |
author_facet | Álvarez–Narváez, S. Berghaus, L. J. Morris, E. R. A. Willingham-Lane, J. M. Slovis, N. M. Giguere, S. Cohen, N. D. |
author_sort | Álvarez–Narváez, S. |
collection | PubMed |
description | The practice of prophylactic administration of a macrolide antimicrobial with rifampin (MaR) to apparently healthy foals with pulmonary lesions identified by thoracic ultrasonography (i.e., subclinically pneumonic foals) is common in the United States. The practice has been associated epidemiologically with emergence of R. equi resistant to MaR. Here, we report direct evidence of multi-drug resistance among foals treated with MaR. In silico and in vitro analysis of the fecal microbiome and resistome of 38 subclinically pneumonic foals treated with either MaR (n = 19) or gallium maltolate (GaM; n = 19) and 19 untreated controls was performed. Treatment with MaR, but not GaM, significantly decreased fecal microbiota abundance and diversity, and expanded the abundance and diversity of antimicrobial resistance genes in feces. Soil plots experimentally infected with Rhodococcus equi (R. equi) and treated with MaR selected for MaR-resistant R. equi, whereas MaR-susceptible R. equi out-competed resistant isolates in GaM-treated or untreated plots. Our results indicate that MaR use promotes multi-drug resistance in R. equi and commensals that are shed into their environment where they can persist and potentially infect or colonize horses and other animals. |
format | Online Article Text |
id | pubmed-6976650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-69766502020-01-29 A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance Álvarez–Narváez, S. Berghaus, L. J. Morris, E. R. A. Willingham-Lane, J. M. Slovis, N. M. Giguere, S. Cohen, N. D. Sci Rep Article The practice of prophylactic administration of a macrolide antimicrobial with rifampin (MaR) to apparently healthy foals with pulmonary lesions identified by thoracic ultrasonography (i.e., subclinically pneumonic foals) is common in the United States. The practice has been associated epidemiologically with emergence of R. equi resistant to MaR. Here, we report direct evidence of multi-drug resistance among foals treated with MaR. In silico and in vitro analysis of the fecal microbiome and resistome of 38 subclinically pneumonic foals treated with either MaR (n = 19) or gallium maltolate (GaM; n = 19) and 19 untreated controls was performed. Treatment with MaR, but not GaM, significantly decreased fecal microbiota abundance and diversity, and expanded the abundance and diversity of antimicrobial resistance genes in feces. Soil plots experimentally infected with Rhodococcus equi (R. equi) and treated with MaR selected for MaR-resistant R. equi, whereas MaR-susceptible R. equi out-competed resistant isolates in GaM-treated or untreated plots. Our results indicate that MaR use promotes multi-drug resistance in R. equi and commensals that are shed into their environment where they can persist and potentially infect or colonize horses and other animals. Nature Publishing Group UK 2020-01-22 /pmc/articles/PMC6976650/ /pubmed/31969575 http://dx.doi.org/10.1038/s41598-020-57479-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Álvarez–Narváez, S. Berghaus, L. J. Morris, E. R. A. Willingham-Lane, J. M. Slovis, N. M. Giguere, S. Cohen, N. D. A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title | A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title_full | A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title_fullStr | A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title_full_unstemmed | A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title_short | A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance |
title_sort | common practice of widespread antimicrobial use in horse production promotes multi-drug resistance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976650/ https://www.ncbi.nlm.nih.gov/pubmed/31969575 http://dx.doi.org/10.1038/s41598-020-57479-9 |
work_keys_str_mv | AT alvareznarvaezs acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT berghauslj acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT morrisera acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT willinghamlanejm acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT slovisnm acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT gigueres acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT cohennd acommonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT alvareznarvaezs commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT berghauslj commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT morrisera commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT willinghamlanejm commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT slovisnm commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT gigueres commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance AT cohennd commonpracticeofwidespreadantimicrobialuseinhorseproductionpromotesmultidrugresistance |